Türk toplumundaki inflamatuar bağırsak hastalığının hastalık mekanizmasında COX-2 gen varyantlarının rolü
Amaç: İnflamatuar bağırsak hastalığı, gastrointestinal sistemde etiolojisi tam olarak bilinmeyen bir hastalık grubu olup, Crohn hastalığı ve ülseratif kolit olmak üzere iki önemli tipe ayrılmaktadır. COX-2 kolon kanserinin de dahil olduğu karsinogenez prosesinde rolü olan ve tümör gelişimine katkı sağlayan bir mediatördür. Aynı zamanda, inflamasyon meydana geldiğinde kolonik mukoza üzerindeki stabiliteyi değiştirdiği bilinmektedir. Bu amaçla, çalışmamızda inflamatuar barsak hastalığı ile COX-2 ilişkisinin Türk kökenli kişiler üzerinde araştırılması amaçlanmıştır. Yöntemler: Çalışmaya 42 Crohn ve 64 ülseratif kolitli hasta olmak üzere toplam 106 hasta) ve 121 sağlıklı kontrol dahil edilmiştir. COX-2 -765G→C ve COX-2 -1195A→G gen varyantları polimeraz zincir reaksiyonu ve restriksiyon parça uzunluk polimorfizmi teknikleri kullanılarak analiz edilmiştir. Bulgular: COX-2-1195A→G gen varyantı AA taşıyıcılarının istatistiksel olarak hasta grubunda (Crohn hastalığı için p=0,008 ve ülseratif kolit için p=0,001) kontrol grubuna göre yüksek bulunmuştur. Buna karşılık olarak AG genotipi ve G taşıyıcıları da kontrol grubunda anlamlı olarak yüksek bulunmuştur (Crohn hastalığı: p=0,005 AG için ve p= 0,008 G için; ülseratif kolit: p=0,001 AG için ve p=0,001G için). Sonuç: Çalışmada Türk kökenli kişiler üzerinde, inflamatuar bağırsak hastalığı ve COX-2 arasındaki ilişkiye dair COX-2-1195A→G AA taşıyıcıları gibi önemli ve araştırılması gerekli soruları beraberinde getiren bulgular elde edilmiştir. Hasta sayısının arttırılarak ek çalışmalar ile hastalık patogonezindeki rolünün tam olarak araştırılması gerektiği düşünülmektedir.
The role of COX-2 gene variants on the disease mechanism of inflammatory bowel disease in a Turkish population
Aim: Inflammatory bowel disease has two major types: Crohn’s disease and ulcerative colitis that occur in thegastrointestinal tract with unknown etiology. COX-2 has important role on carcinogenesis process includingcolon cancer supporting the tumor growth. COX-2 was also known due to its ability to change homeostasis oncolonic mucosa in inflammatory cells on patients who have inflammatory bowel disease. In this study, we haveaimed to find a linkage between inflammatory bowel disease and COX-2 in a Turkish population.Methods:A total of 106 patients,42 with Crohn’s disease and 64 with ulcerative colitis and 121 healthy controlsubjects were included the study. Gene variants of COX-2-765G→C and COX-2-1195A→G were analyzed bypolymerase chain reaction and restriction fragment length polymorphism techniques.Results: The results demonstrated that COX-2-1195A→G gene variants AA carriers were statistically found inhigh level on patients with both ulcerative colitis (p=0.001) and Crohn’s disease (p=0.008). In contrast, AGgenotype and G carriers were statistically found higher in control group (Crohn’s disease, p=0.005 for AG andp= 0.008 for G; ulcerative colitis, p=0.001 for AG and p=0.001 for G).Conclusion: In this research, we have observed important and questionable results between inflammatory boweldisease and COX-2, especially COX-2-1195A→G gene variants AA carriers in a Turkish population.Researches need to focus on their local roles on inflammatory bowel disease pathogenesis with large samplesize.
___
- Sleizenger & Fordtran’s, Gastrointestinal and Liver Disease 7th
Edition, Saunders Elsevier, Philadelphia .Volume I, pp. 2005–67.
- Peña-Sánchez JN, Lix LM, Teare GF, Li W, Fowler SA, Jones JL.
Impact of an Integrated Model of Care on Outcomes of Patients With
Inflammatory Bowel Diseases: Evidence From a Population-Based
Study. J Crohns Colitis. 2017;11:1471-9.
- Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in
ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35.
- Higashi D, Futami K, Ishibashi Y, Egawa Y, Maekawa T, Matsui T,
Iwashita A, et al. Clinical course of colorectal cancer in patients with
ulcerative colitis. Anticancer Res. 2011;31:2499–504.
- Lesage S, Zouali H, Cézard JP, Colombel JF, Belaiche J, Almer S, et
al. CARD15/NOD2 mutational analysis and genotype-phenotype
correlation in 612 patients with inflammatory bowel disease. Am J
Hum Genet. 2002;70:845-57.
- Olén O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, et
al. Childhood onset inflammatory bowel disease and risk of cancer: a
Swedish nationwide cohort study 1964-2014. BMJ.
2017;20:358:j3951.
- Jewel Samadder N, Valentine JF, Guthery S, Singh H, Bernstein CN,
Wan Y, et al. Colorectal Cancer in Inflammatory Bowel Diseases: A
Population-Based Study in Utah. Dig Dis Sci. 2017;62:2126-32.
- Luo C, Zhang H. The Role of Proinflammatory Pathways in the
Pathogenesis of Colitis-Associated Colorectal Cancer. Mediators
Inflamm. 2017;2017:5126048.
- Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm
M, et al. Severity of inflammation is a risk factor for colorectal
neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–9.
- Wang R, Leong RW. Primary sclerosing cholangitis as an independent
risk factor for colorectal cancer in the context of inflammatory bowel
disease: a review of the literature. World J Gastroenter. 2014;20:8783–
9
- Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K,
et al. Ulcerative colitis-associated colorectal cancer shows a poorer
survival than sporadic colorectal cancer: a nationwide Japanese study.
Inflamm Bowel Dis. 2011;17:802–8.
- Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y. Identification of
functional genetic variants in cyclooxygenase-2 and their association
with risk of esophageal cancer. Gastroenterology. 2005;129:565–76.
- Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in
patients with inflammatory bowel disease: a population based study.
Cancer. 2001;91:854-62.
- Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Jewell D. Cancer in
patients with ulcerative colitis, Crohn’s disease and coeliac disease:
record linkage study. Eur J Gastroenterol Hepatol. 2008;20:297-304.
- Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, et
al. CESAME Study Group. Risk of colorectal high-grade dysplasia and
cancer in a prospective observational cohort of patients with
inflammatory bowel disease. Gastroenterology. 2013;145:166-175.e8.
- Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg
R,et al. Family history as a risk factor for colorectal cancer in
inflammatory bowel disease. Gastroenterology. 2001;120:1356-62.
- Thompson PA, Ashbeck EL, Roe DJ, Fales L, Buckmeier J, Wang F, et
al. Celecoxib for the Prevention of Colorectal Adenomas: Results of a
Suspended Randomized Controlled Trial. J Natl Cancer Inst.
2016;108:pii:djw151.
- Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y, et al. Aspirin use after
diagnosis but not prediagnosis improves established colorectal cancer
survival: a meta-analysis. Gut. 2015;64:1419-25.
- Connell W, Leong RW, Walsh A, Kamm M, Kench J, What should be
the protocol to manage indefinite dysplasia in IBD?
http://wiki.cancer.org.au/australiawiki/index.php?oldid=17938, 2012.
- Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson
WF, Cyclooxygenase 2 is induced in colonicepithelial cells in
inflammatory bowel disease. Gastroenterology. 1998;115:297–306.
- Smythe EM, Burke A, FitzGerald GA. Lipid-derived autacoids:
eicosanoids and platelet-activating factor. In: Goodman & Gilman’s
The Pharmacological Basis of Therapeutics, edited by Brunton LL,
Lazo JS, Parker KL. New York: McGraw-Hill, 2005, pp. 653–70.
- Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C.
Differential inhibition of human prostaglandin endoperoxide synthase1
and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol.
1997;48:623–31.
- Vane JR, Botting RM. New insights into the mode of action of
antiinflammatory drugs. Inflamm Res. 1995;44:1–10.
- Needleman P, Isakson PC. The discovery and function of COX-2. J
Rheumatol. 1997;49:6–8.
- Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al.
Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs:
insight into mechanisms and implications for cancer growthand ulcer
healing. Nat Med. 1999;5:1418–23.
- Hatazawa R, Tanaka A, Tanigami M, Amagase K, Kato S, Ashida Y,
Takeuchi K. Cyclooxygenase-2/prostaglandin E2 accelerates the
healing of gastric ulcers via EP4 receptors. Am J Physiol Gastrointest
Liver Physiol. 2007;293:G788–G797.
- Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H,
et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its
inhibition by the specific antagonist delays healing in mice.
Gastroenterology. 1997;112:387–97.
- Ukawa H, Yamakuni H, Kato S, Takeuchi K. Effects of
cyclooxygenase- 2 selective and nitric oxide-releasing nonsteroidal
antiinflammatory drugs on mucosal ulcerogenic and healing responses
of the stomach. DigDis Sci. 1998;43:2003–11.
- Andersen V, Nimmo E, Krarup HB, Drummond H, Christensen J, Ho
GT, et al. Cyclooxygenase-2 (COX-2) polymorphisms and risk of
inflammatory bowel disease in a Scottish and Danish case-control
study. Inflamm Bowel Dis. 2011;17:937-46.
- Zhang CX, Guo LK, Guo XF. Interaction between the polymorphisms
of cyclooxygenase-2-1195G/A,MnSOD9Ala/val genes and the high-fat
diets and its correlation with ulcerative colitis. Zhongguo Yi Xue Ke
Xue Yuan Xue Bao 2015;37: 37-43.
- de Vries HS, te Morsche RH, van Oijen MG, Nagtegaal ID, Peters
WH, de Jong DJ.The functional -765G→C polymorphism of the COX2
gene may reduce the risk of developing crohn's disease. PLoS One.
2010;5:e15011.
- Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in
inflammation, cancer, and development. Oncogene. 1999;8:7908-16.
- Zhu W, Wei BB, Shan X, Liu P. -765G>C and 8473T> C
polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33
case–control studies. Mol Biol Rep. 2009;37:277–88.
- Watanabe J, Lin JA, Narasimha AJ, Shahbazian A, Ishikawa T,
Martin MG, et al. Novel anti-inflammatory functions for endothelial
and myeloid cyclooxygenase-2 in a new mouse model of Crohn’s
disease. Am J Physiol Gastrointest Liver Physiol. 2010;298:G842–
G850.